Encounter for screening for metabolic disorder
ICD-10 Z13.22 is a billable code used to indicate a diagnosis of encounter for screening for metabolic disorder.
Z13.22 is used to indicate an encounter for screening for metabolic disorders, which are conditions that disrupt normal metabolism, the process of converting food to energy on a cellular level. This screening is crucial for early detection and management of disorders such as diabetes, obesity, and dyslipidemia. Factors influencing health status include genetics, lifestyle choices, and environmental factors, which can all contribute to metabolic disorders. Social determinants of health, such as socioeconomic status, access to healthcare, and education, play a significant role in an individual's risk for these conditions. Preventive care through regular screenings can help identify at-risk individuals, allowing for timely interventions that can mitigate long-term health complications. Documentation must reflect the reason for the screening, any relevant patient history, and the results of the screening tests to ensure accurate coding and reimbursement.
Documentation should include patient history, risk factors, and results of the screening tests. It is essential to note any referrals made for further evaluation.
Routine checkups where metabolic screening is indicated based on age or risk factors, follow-up visits for abnormal screening results.
Consideration of social determinants such as access to healthy food and exercise opportunities, which may influence metabolic health.
Documentation should focus on population health data, screening rates, and outcomes to track public health trends.
Community health screenings, epidemiological studies assessing metabolic disorder prevalence.
Emphasis on health equity and addressing barriers to screening in underserved populations.
Used during a screening visit for metabolic disorders to assess cholesterol levels.
Document the reason for the lipid panel and any relevant patient history.
Primary care providers should ensure that the lipid panel is part of a comprehensive metabolic screening.
Z13.22 should be used during encounters specifically for screening for metabolic disorders, particularly when no current diagnosis exists, and preventive measures are being taken.
